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Abstract 
 
Purpose: To report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional 
immunosuppressants, with subsequent remission following treatment with alemtuzumab. 
Methods: Case report. Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-
CD52 monoclonal antibody that has recently been approved for use in relapsing MS. 
Results: A 17-year old female presented with bilateral optic neuritis and subsequently bilateral 
intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for 
which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to 
conventional immunosuppressants responded to alemtuzumab, inducing remission. 
Conclusions: To our knowledge this is the first such report of alemtuzumab treatment in MS-
associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related 
conditions. 
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Introduction 
 
Alemtuzumab is an anti-CD52 monoclonal antibody recently approved for use in relapsing multiple 
sclerosis (MS). It has been shown to be highly effective at reducing clinical relapse rates and in some 
studies slowing, or even reversing, disability outcomes.[1-3] CD52 is present on approximately 5% of 
the cell surface of lymphocytes and is also expressed, albeit at lower levels, on monocytes, 
macrophages, eosinophils and NK cells.[4,5] Treatment with alemtuzumab results in a rapid depletion 
of circulating lymphocytes with subsequent beneficial reconstitution.[6] 
 
Optic neuritis is the most commonly associated ocular manifestation of MS, however intraocular 
inflammation is reported to occur in 0.4% to 26.9% of patients.[7] Intermediate uveitis is the most 
common type but all anatomic sub-types of uveitis have been reported.[7,8] Secondary complications 
including cystoid macular oedema can also occur; at which point the disease is difficult to manage and 
may be refractory to standard immunosuppressive treatments.[7,8] Although the exact prevalence of 
macular oedema in MS-associated uveitis is unknown, it is estimated to affect 37% of patients with 
MS-associated intermediate uveitis.[8] Alemtuzumab has previously been shown to be beneficial in 
ocular inflammatory disease initially in a single case refractory to treatment and complicated by 
standard therapeutic side effects, then a case series of 10 patients with systemic autoimmune disease 
and associated ocular inflammatory disease and finally in 18 patients with Behçet’s disease.[9-11] 
 
Although the association between MS and uveitis is well established, the effect of alemtuzumab on 
MS-associated intraocular inflammation is unknown. We present a patient with MS and alemtuzumab-
induced remission of uveitis. 
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Case report 
 
A 17-year-old female presented with an episode of optic neuritis (ON) affecting the right eye, followed 
by ON of the left eye 10 months later. One month after this she was diagnosed with bilateral 
intermediate uveitis with peripheral retinal vasculitis and associated macular oedema (figure 1). 
Routine uveitis screening was performed to exclude common systemic associations. Syphilis serology, 
antinuclear and antinuclear cytoplasmic antibodies and QuantiFERON® Gold tests were negative, and 
a chest X-ray was unremarkable. Following initial screening she was referred for a neurological 
opinion. Subsequent cranial magnetic resonance imaging (MRI) was normal with an unremarkable 
cerebrospinal fluid examination other than positive CSF oligoclonal bands unpaired in a serum sample. 
For her ophthalmological symptoms the patient commenced immunomodulatory treatment with a 
combination of oral prednisolone and cyclosporine, which was then switched to tacrolimus. 
 
Three years after initial presentation the patient experienced transient limb sensory symptoms with a 
repeat cranial MRI scan demonstrating a single, left sided deep white matter lesion as well as non-
specific abnormal cord signal at C6. In the following 3 years the patient experienced a further 5 
episodes of transient neurological dysfunction including 4 in one 12-month period. A further MRI 
demonstrated new lesions in the medulla, cerebellum, anterior pons and in the left periventricular 
region and a diagnosis of relapsing-MS was made. Of note, high resolution computerised tomography 
of the thorax and anti-aquaporin-4 antibodies were negative. 
 
As a result of highly active disease, alemtuzumab was commenced with a 5-day treatment of 12mg/day 
intravenously with a routine, second, 3-day course of alemtuzumab 12 months later. Following a 
further clinical relapse 3 years after treatment initiation and repeat imaging demonstrating new and 
enhancing lesions the patient received a 3rd, 3-day course of alemtuzumab. 
 
Ophthalmological management has proved difficult throughout with the patient requiring regular 
courses of oral steroids and been intolerant/failed treatment with cyclosporine, tacrolimus and 
mycophenolate mofetil after. In particular, the left eye required periocular and intraocular steroids 
(Figure 2). After the first course of alemtuzumab, macular oedema was present in the left eye despite 
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two orbital floor injections of triamcinolone for approximately 6 months after infusion. Following this, 
visual acuity and central macular thickness remained stable until the second course of alemtuzumab.  
Following the second treatment, the patient experienced a flare in symptoms lasting approximately 3 
months. However, stabilisation of disease was again observed for a period of 9 months. Macular 
oedema subsequently worsened, was difficult to control and required an intraocular dexamethasone 
implant in order to control the inflammation in the left eye.  Following this she received the 3rd course 
of alemtuzumab and despite the effect of intraocular dexamethasone wearing off she has remained well 
controlled for the last 12 months not even requiring oral steroids. Recent ophthalmological review has 
demonstrated stable vision with OCT showing a healthy macular in the right eye and minute cysts in 
the left eye. Of note, the patient has developed Graves’ disease with associated thyroid eye disease 
following the second course of alemtuzumab; a well described autoimmune side effect of the drug. 
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Discussion 
 
We present a case of MS-associated uveitis refractory to conventional immunomodulatory therapy with 
subsequent remission achieved following alemtuzumab treatment. Alemtuzumab has previously been 
used for treating intraocular inflammation, albeit with scarce case series and case reports in the 
literature but with promising results.[9-11] In contrast to previously reported cases in which patients 
received 1 cycle of treatment, our patient received 3 cycles of treatment. In our patient the macular 
oedema resolved and improvement was maintained for approximately 6 months after the addition of 
alemtuzumab without other significant changes on the systemic or local treatment after the first and the 
second infusion of alemtuzumab. Similarly in a case report using alemtuzumab for undifferentiated 
unilateral panuveitis, the patient experienced 2 flare-ups of intraocular inflammation during the 4 
months after treatment with posterior induced remission, which coincides with the response in our 
patient.[10]  
 
Uveitis is traditionally considered an autoimmune disease initiated by loss of immune tolerance to 
retinal proteins and tyrosinase-related products, orchestrated by two subsets of CD4+ T cells: Th1 and 
Th17 cells.[12] The mechanism of action of alemtuzumab helps to explain its potential effect on 
uveitis. Following treatment with alemtuzumab there is a rapid and profound reduction in lymphocytes 
with recovery varying by cell type. B lymphocytes recover the quickest, followed by CD8+ and CD4+ 
T lymphocytes.[13-15] The population of lymphocytes is altered following treatment, with regulatory 
T cells (Tregs) dominating the milieu, which is thought to be beneficial.[16-18] This time to 
repopulation with Tregs may explain the delayed effect seen on ocular disease in our case. 
 
The main side effects of alemtuzumab are well established and relate to acquired autoimmune diseases, 
with a particular predilection for the thyroid gland.[19] Although serious, these side effects are 
predictable and can be anticipated with an active surveillance program. Despite these side effects, this 
case demonstrates the potential utility of alemtuzumab for treatment of MS-associated uveitis, which 
was more efficacious than all other standard immunomodulatory treatment used. Patients with 
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concomitant MS and uveitis may therefore expect improvement in ocular symptoms following 
treatment with alemtuzumab. 
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 Figure Captions: 
 
 
Fig 1 Fluorescein angiography (FA) and optical coherence tomography (OCT) at presentation. Top 
figures show FA for the right and left eye with peripheral vascular leakage, macular leakage and 
hyperfluorescent optic disc in both eyes. Inferior figures show the OCT at the level of the fovea 
disclosing bilateral macular oedema. A and C corresponds to images of the right eye and B and D to 
the left eye. 
 
 
Fig 2 Visual acuity (VA) and central macular thickness (CMT) diagrams, showing the evolution of 
both parameters during the follow-up. Arrows sign the changes on treatment according to the superior 
legend. Vertical lines in the graphs represent a time interval of approximately 6 months. RE: right eye; 
LE: left eye; VA: visual acuity; CMT: central macular thickness.
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